Literature DB >> 22137740

Old and new heparins.

Benilde Cosmi1, Gualtiero Palareti.   

Abstract

Heparin is an effective, relatively safe, inexpensive parenteral antithrombotic agent widely used in the prevention and treatment of thromboembolic disorders, but it has several limitations such as the marked intra- and inter-patient variability in its anticoagulant response, its poor bioavailability at low doses and its relatively narrow risk to benefit ratio. Low molecular weight heparins ( LMWHs), ultra LMWHs and synthetic pentasaccharides have been developed from heparin to overcome its limitations. The characteristics of these compounds are reviewed along with the description of their approved clinical uses.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137740     DOI: 10.1016/j.thromres.2011.11.008

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Thrombolysis by chemically modified coagulation factor Xa.

Authors:  E L G Pryzdial; S C Meixner; K Talbot; L J Eltringham-Smith; J R Baylis; F M H Lee; C J Kastrup; W P Sheffield
Journal:  J Thromb Haemost       Date:  2016-08-17       Impact factor: 5.824

2.  Preparation of low molecular weight heparin using an ultrasound-assisted Fenton-system.

Authors:  Zijian Zhi; Junhui Li; Jianle Chen; Shan Li; Huan Cheng; Donghong Liu; Xingqian Ye; Robert J Linhardt; Shiguo Chen
Journal:  Ultrason Sonochem       Date:  2018-11-20       Impact factor: 7.491

3.  Anticoagulation for noncardiac indications in neurologic patients: comparative use of non-vitamin k oral anticoagulants, low-molecular-weight heparins, and warfarin.

Authors:  Ariela L Marshall; Jean-Marie Connors
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

4.  Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.

Authors:  Shahla K Alalaf; Rojan K Jawad; Parez R Muhammad; Mahabad S Ali; Namir G Al Tawil
Journal:  BMC Pregnancy Childbirth       Date:  2015-03-28       Impact factor: 3.007

5.  Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients.

Authors:  Mohamed Sayed Abbas
Journal:  Indian J Crit Care Med       Date:  2017-07

Review 6.  Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.

Authors:  Nipa Banik; Seong-Bin Yang; Tae-Bong Kang; Ji-Hong Lim; Jooho Park
Journal:  Int J Mol Sci       Date:  2021-09-29       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.